Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azvudine pharmacokinetics in healthy adults and elderly
NCT06991634Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Apr 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of azvudine (2 arms), sponsored by Genuine Biotech. Primary endpoints: Maximum Plasma Concentration at 36 hours, Area Under the Plasma Concentration Curve at 36 hours and 2 more. Started Apr 2023; status: completed.
02
Drugs
azvudine
Beyond the preview
Go deeper on NCT06991634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991634.